Iovance Biotherapeutics Inc. has released a corporate presentation detailing its achievements and ongoing initiatives in the field of Tumor Infiltrating Lymphocytes $(TIL)$ therapy for cancer treatment. The company has treated over 1,000 commercial and clinical patients with its TIL products and reported more than $210 million in total product revenue. Their portfolio includes two approved products and numerous clinical trials across various cancer types, including advanced melanoma and non-small cell lung cancer. Iovance is actively involved in regulatory filings beyond the U.S. and continues to expand its treatment centers globally. The presentation highlights the company's focus on developing innovative therapies to address unmet medical needs. You can access the full presentation through the link below.